STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
STREAM is inviting applications for two postdoctoral research fellows with a background in research ethics, epidemiology, biostatistics, or meta-research.
See here for more details on the position and application process.
Zhang SX, Fergusson D, Kimmelman J. Proportion of Patients in Phase 1 Oncology Trials Receiving Treatments that are Ultimately Approved. Journal of the National Cancer Institute. April 1, 2020.
Carlisle BG, Doussau A, Kimmelman J. Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. BMJ Open. February 17, 2020.
Federico C, Mogil JS, Ramsay T, Fergusson DA, Kimmelman J. A systematic review and meta-analysis of pregabalin preclinical studies. Pain. January 22, 2020.
Hutchinson N, Vinarov E, Iasonos A, Kimmelman J. Ethical and Policy Issues for Seamless Phase I Oncology Trials. Journal of Clinical Oncology. December 26, 2019.
Feustel AC, MacPherson A, Fergusson DA, Kieburtz K, Kimmelman J. Risks and benefits of unapproved, disease-modifying treatments for neurodegenerative disease. Neurology. December 2, 2019.
Rezak M, de Carvalho M. Disease modification in neurodegenerative diseases: Not quite there yet. Neurology. December 2, 2019.
Sarvas H, Carlisle B, Dolter S, Vinarov E, Kimmelman J. Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. Journal of the National Cancer Institute. November 13, 2019.
Carlisle BG, Zheng T, Kimmelman J. Imatinib and the long tail of targeted drug development. Nature Reviews Clinical Oncology. October 24, 2019.
Doussau A, Vinarov E, Barsanti-Innes B, Kimmelman J. Comparison between protocols and publications for prognostic and predictive cancer biomarker studies. Clinical Trials. October 5, 2019.
Carlisle BG, Doussau A, Kimmelman J. Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials. October 3, 2019.
Kimmelman J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nature Reviews Clinical Oncology. August 30, 2019.
London AJ, Kimmelman J. Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. Hastings Center Report. August 20, 2019.
In Hunting for Cures, Ethics Can Strengthen Clinical Trials. Carnegie Mellon News. November 6, 2019.
MacPherson A, Kimmelman J. Ethical development of stem-cell-based interventions. Nature Medicine. July 3, 2019.
Jonathan Kimmelman quoted in Dallas News on the inconclusive evidence around experimental Covid-19 interventions.
Jonathan Kimmelman quoted in Clinical Research News on the distinction between research and care in the context of the WHO's malaria vaccine implementation programme.
Jonathan Kimmelman quoted in Vox on the ethical obligation to practice social distancing during the Covid-19 pandemic.
Jonathan Kimmelman quoted in STAT News on a first-in-human trial of an experimental Covid-19 vaccine without prior animal testing.
Jonathan Kimmelman quoted in BMJ on the ethics of the WHO's malaria vaccine study.
Jonathan Kimmelman quoted in Bloomberg on the selection of drugs and combinations for clinical testing in cancer patients.
Jonathan Kimmelman quoted in Nature on placebo-controlled clinical trials for regenerative medicine in an article on Japan's regulation of cell-based interventions.
Jonathan Kimmelman quoted in Neurology Today on the risks and benefits of Alzheimer's prevention trials.
Jonathan Kimmelman quoted in Nature on the use of registries for preclinical trials.
Jonathan Kimmelman quoted in Chemistry World on the hype surrounding unproven stem-cell based interventions.
Jonathan Kimmelman quoted in Bloomberg on the ethics of genetic medicine.